New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareBronchogen vs Thymosin Alpha-1

Bronchogen vs Thymosin Alpha-1

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Bronchogen
Immune SupportAnti-Aging & Longevity
Thymosin Alpha-1
Summary
Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
Half-Life
Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
2–3 hours
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
0.8–1.6 mg
Frequency
Daily for 10–30 days
Twice weekly
Key Benefits
  • Tissue-specific support for bronchial and lung health
  • Promotes normalization of bronchial epithelial cell function
  • Potential benefits in chronic bronchitis and COPD support
  • Anti-aging effects on pulmonary tissue
  • May reduce frequency of respiratory infections
  • Supports lung function preservation with aging
  • Compatible with other Khavinson bioregulator peptides
  • Enhances T-cell and NK cell activity
  • Supports recovery from viral and bacterial infections
  • May reduce inflammation systemically
  • Supports healthy aging and immune resilience
  • Improves vaccine response
  • Supports liver health
  • May help with chronic fatigue syndrome and post-viral conditions
  • Approved in multiple countries for hepatitis B and C treatment
Side Effects
  • Generally well tolerated in research studies
  • Mild local reactions at injection site (if injected)
  • No significant systemic side effects reported at standard doses
  • Injection site irritation
  • Mild flu-like symptoms initially (immune activation)
  • Fatigue (rare)
Stacks With